
In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.























This study analyzes the effect of a managed care program on Medicaid expenditures for children with special healthcare needs using a quasi-experimental design.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
